{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:05:27Z","timestamp":1791475527578,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41401-025-01657-w","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:02:05Z","timestamp":1759312925000},"page":"504-517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Discovery and characterization of a novel HIF-2\u03b1 agonist for the treatment of CKD-related renal anemia"],"prefix":"10.1038","volume":"47","author":[{"given":"Shu-qing","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-zhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bu-ying","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-hang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-xin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-tong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-yue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"1657_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1357-2725(03)00211-5","volume":"36","author":"RJ Kewley","year":"2004","unstructured":"Kewley RJ, Whitelaw ML, Chapman-Smith A. The mammalian basic helix-loop-helix\/PAS family of transcriptional regulators. Int J Biochem Cell Biol. 2004;36:189\u2013204.","journal-title":"Int J Biochem Cell Biol"},{"key":"1657_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nature14883","volume":"524","author":"D Wu","year":"2015","unstructured":"Wu D, Potluri N, Lu JP, Kim YC, Rastinejad F. Structural integration in hypoxia-inducible factors. Nature. 2015;524:303\u20138.","journal-title":"Nature"},{"key":"1657_CR3","doi-asserted-by":"publisher","first-page":"15504","DOI":"10.1073\/pnas.2533374100","volume":"100","author":"PJ Erbel","year":"2003","unstructured":"Erbel PJ, Card PB, Karakuzu O, Bruick RK, Gardner KH. Structural basis for PAS domain heterodimerization in the basic helix-loop-helix-PAS transcriptin factor hypoxia-inducible factor. Proc Natl Acad Sci USA. 2003;100:15504\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1657_CR4","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1073\/pnas.082121399","volume":"99","author":"SA Dames","year":"2002","unstructured":"Dames SA, Martinez-Yamout M, De Guzman RN, Dyson HJ, Wright PE. Structural basis for Hif-1\u03b1\/CBP recognition in the cellular hypoxic response. Proc Natl Acad Sci USA. 2002;99:5271\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1657_CR5","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1126\/science.1066373","volume":"294","author":"RK Bruick","year":"2001","unstructured":"Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294:1337\u201340.","journal-title":"Science"},{"key":"1657_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271\u20135.","journal-title":"Nature"},{"key":"1657_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/35017054","volume":"2","author":"M Ohh","year":"2000","unstructured":"Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000;2:423\u20137.","journal-title":"Nat Cell Biol"},{"key":"1657_CR8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1126\/science.1059796","volume":"292","author":"P Jaakkola","year":"2001","unstructured":"Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468\u201372.","journal-title":"Science"},{"key":"1657_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41580-020-0227-y","volume":"21","author":"P Lee","year":"2020","unstructured":"Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol. 2020;21:268\u201383.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1657_CR10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jfma.2018.03.017","volume":"117","author":"HM Shih","year":"2018","unstructured":"Shih HM, Wu CJ, Lin SL. Physiology and pathophysiology of renal erythropoietin-producing cells. J Formos Med Assoc. 2018;117:955\u201363.","journal-title":"J Formos Med Assoc"},{"key":"1657_CR11","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nrneph.2015.82","volume":"11","author":"MJ Koury","year":"2015","unstructured":"Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol. 2015;11:394\u2013410.","journal-title":"Nat Rev Nephrol"},{"key":"1657_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/ki.2011.77","volume":"80","author":"SE Quaggin","year":"2011","unstructured":"Quaggin SE, Kapus A. Scar wars: mapping the fate of epithelial-mesenchymal-myofibroblast transition. Kidney Int. 2011;80:41\u201350.","journal-title":"Kidney Int"},{"key":"1657_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","volume":"11","author":"VH Haase","year":"2021","unstructured":"Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl. 2021;11:8\u201325.","journal-title":"Kidney Int Suppl"},{"key":"1657_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/ki.2011.500","volume":"81","author":"IC Macdougall","year":"2012","unstructured":"Macdougall IC, Roger SD, de Francisco A, Goldsmith DJA, Schellekens H, Ebbers H, et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int. 2012;81:727\u201332.","journal-title":"Kidney Int"},{"key":"1657_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-023-00848-6","volume":"23","author":"X Yuan","year":"2024","unstructured":"Yuan X, Ruan W, Bobrow B, Carmeliet P, Eltzschig HK. Targeting hypoxia-inducible factors: therapeutic opportunities and challenges. Nat Rev Drug Discov. 2024;23:175\u2013200.","journal-title":"Nat Rev Drug Discov"},{"key":"1657_CR16","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1073\/pnas.0608382104","volume":"104","author":"M Gruber","year":"2007","unstructured":"Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci USA. 2007;104:2301\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1657_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1146\/annurev-pharmtox-010818-021637","volume":"59","author":"GL Semenza","year":"2019","unstructured":"Semenza GL. Pharmacologic targeting of hypoxia-inducible factors. Annu Rev Pharmacol Toxicol. 2019;59:379\u2013403.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1657_CR18","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1152\/ajprenal.00174.2010","volume":"299","author":"VH Haase","year":"2010","unstructured":"Haase VH. Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Ren Physiol. 2010;299:F1\u201313.","journal-title":"Am J Physiol Ren Physiol"},{"key":"1657_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1620\/tjem.235.233","volume":"235","author":"N Suzuki","year":"2015","unstructured":"Suzuki N. Erythropoietin gene expression: developmental-stage specificity, cell-type specificity, and hypoxia inducibility. Tohoku J Exp Med. 2015;235:233\u201340.","journal-title":"Tohoku J Exp Med"},{"key":"1657_CR20","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1158\/0008-5472.CAN-05-3241","volume":"66","author":"EB Rankin","year":"2006","unstructured":"Rankin EB, Tomaszewski JE, Haase VH. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res. 2006;66:2576\u201383.","journal-title":"Cancer Res"},{"key":"1657_CR21","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1096\/fj.04-1640fje","volume":"18","author":"C Warnecke","year":"2004","unstructured":"Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, et al. Differentiating the functional role of hypoxia-inducible factor (HIF)-1\u03b1 and HIF-2\u03b1 (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2\u03b1 target gene in Hep3B and Kelly cells. FASEB J. 2004;18:1462\u20134.","journal-title":"FASEB J"},{"key":"1657_CR22","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/emboj\/cdg117","volume":"22","author":"M Morita","year":"2003","unstructured":"Morita M, Ohneda O, Yamashita T, Takahashi S, Suzuki N, Nakajima O, et al. HLF\/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 2003;22:1134\u201346.","journal-title":"EMBO J"},{"key":"1657_CR23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41589-019-0234-5","volume":"15","author":"D Wu","year":"2019","unstructured":"Wu D, Su X, Lu J, Li S, Hood BL, Vasile S, et al. Bidirectional modulation of HIF-2 activity through chemical ligands. Nat Chem Biol. 2019;15:367\u201376.","journal-title":"Nat Chem Biol"},{"key":"1657_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116227","volume":"268","author":"S Chen","year":"2024","unstructured":"Chen S, Liu Y, Wang Z, Qi C, Yu Y, Xu L, et al. Identification of 3-aryl-5-methyl-isoxazole-4-carboxamide derivatives and analogs as novel HIF-2\u03b1 agonists through docking-based virtual screening and structural modification. Eur J Med Chem. 2024;268:116227.","journal-title":"Eur J Med Chem"},{"key":"1657_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112999","volume":"211","author":"Y Yu","year":"2021","unstructured":"Yu Y, Yu Q, Liu S, Wu C, Zhang X. Insight into the binding mode of HIF-2 agonists through molecular dynamic simulations and biological validation. Eur J Med Chem. 2021;211:112999.","journal-title":"Eur J Med Chem"},{"key":"1657_CR26","doi-asserted-by":"publisher","first-page":"17384","DOI":"10.1021\/acs.jmedchem.1c01479","volume":"64","author":"Y Yu","year":"2021","unstructured":"Yu Y, Yang F, Yu Q, Liu S, Wu C, Su K, et al. Discovery of a potent and orally bioavailable hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) agonist and its synergistic therapy with prolyl hydroxylase inhibitors for the treatment of renal anemia. J Med Chem. 2021;64:17384\u2013402.","journal-title":"J Med Chem"},{"key":"1657_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2022.117041","volume":"77","author":"W Song","year":"2023","unstructured":"Song W, Zhuang J, Zhang N, Ren X, Xu W, Guo M, et al. SAR study of 1,2-benzisothiazole dioxide compounds that agonize HIF-2 stabilization and EPO production. Bioorg Med Chem. 2023;77:117041.","journal-title":"Bioorg Med Chem"},{"key":"1657_CR28","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1021\/jm300687e","volume":"55","author":"MM Mysinger","year":"2012","unstructured":"Mysinger MM, Carchia M, Irwin JJ, Shoichet BK. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem. 2012;55:6582\u201394.","journal-title":"J Med Chem"},{"key":"1657_CR29","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1021\/jm901137j","volume":"53","author":"JB Baell","year":"2010","unstructured":"Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010;53:2719\u201340.","journal-title":"J Med Chem"},{"key":"1657_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3\u201326.","journal-title":"Adv Drug Deliv Rev"},{"key":"1657_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.","journal-title":"Sci Rep."},{"key":"1657_CR32","doi-asserted-by":"publisher","first-page":"D1083","DOI":"10.1093\/nar\/gkt1031","volume":"42","author":"AP Bento","year":"2014","unstructured":"Bento AP, Gaulton A, Hersey A, Bellis LJ, Chambers J, Davies M, et al. The ChEMBL bioactivity database: an update. Nucleic Acids Res. 2014;42:D1083\u20131090.","journal-title":"Nucleic Acids Res"},{"key":"1657_CR33","doi-asserted-by":"publisher","first-page":"5930","DOI":"10.1021\/acs.jmedchem.5b00529","volume":"58","author":"TH Scheuermann","year":"2015","unstructured":"Scheuermann TH, Stroud D, Sleet CE, Bayeh L, Shokri C, Wang H, et al. Isoform-selective and stereoselective inhibition of hypoxia inducible factor-2. J Med Chem. 2015;58:5930\u201341.","journal-title":"J Med Chem"},{"key":"1657_CR34","doi-asserted-by":"crossref","unstructured":"Bajusz D, R\u00e1cz A, H\u00e9berger K. Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? J Cheminform. 2015;7:20.","DOI":"10.1186\/s13321-015-0069-3"},{"key":"1657_CR35","unstructured":"Klaus SJ, Molineaux CJ, Neff TB, Guenzler-Pukall V, Parobok IL, Seeley TW, et al, inventors; FibroGen Inc, assignee. Use of hypoxia inducible factor \u03b1 (HIF\u03b1) stabilizers for enhancing erythropoiesis. WO patent 2004108121A1. 2004 Dec 16."},{"key":"1657_CR36","unstructured":"Chai D, Col\u00f3n M, Duffy KJ, Fitch DM, Tedesco R, Zimmerman MN, inventors; SmithKline Beecham Corporation, assignee. Prolyl hydroxylase antagonists. WO patent 2007038571A2. 2007 Apr 5."},{"key":"1657_CR37","unstructured":"Rabinowitz MH, Rosen MD, Tarantino KT, Venkatesan H, inventors; Janssen Pharmaceutica Nv, assignee. 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors. WO patent WO2012021830A1. 2012 Feb 16."},{"key":"1657_CR38","unstructured":"Organisation for Economic Co-operation and Development (OECD). Fish Embryo Acute Toxicity (FET) Test. Test No. 236. OECD Publishing; 2013."},{"key":"1657_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0166-445X(95)00040-B","volume":"34","author":"H Bleau","year":"1996","unstructured":"Bleau H, Daniel C, Chevalier G, van Tra H, Hontela A. Effects of acute exposure to mercury chloride and methylmercury on plasma cortisol, T3, T4, glucose and liver glycogen in rainbow trout (Oncorhynchus mykiss). Aquat Toxicol. 1996;34:221\u201335.","journal-title":"Aquat Toxicol"},{"key":"1657_CR40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ecoenv.2004.10.015","volume":"63","author":"B Fraysse","year":"2006","unstructured":"Fraysse B, Mons R, Garric J. Development of a zebrafish 4-day embryo-larval bioassay to assess toxicity of chemicals. Ecotoxicol Environ Saf. 2006;63:253\u201367.","journal-title":"Ecotoxicol Environ Saf"},{"key":"1657_CR41","doi-asserted-by":"publisher","first-page":"e0192531","DOI":"10.1371\/journal.pone.0192531","volume":"13","author":"A Rahman","year":"2018","unstructured":"Rahman A, Yamazaki D, Sufiun A, Kitada K, Hitomi H, Nakano D, et al. A novel approach to adenine-induced chronic kidney disease associated anemia in rodents. PLoS One. 2018;13:e0192531.","journal-title":"PLoS One"},{"key":"1657_CR42","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ekir.2018.12.006","volume":"4","author":"O Akchurin","year":"2019","unstructured":"Akchurin O, Patino E, Dalal V, Meza K, Bhatia D, Brovender S, et al. Interleukin-6 contributes to the development of anemia in juvenile CKD. Kidney Int Rep. 2019;4:470\u201383.","journal-title":"Kidney Int Rep."},{"key":"1657_CR43","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1042\/CS20190479","volume":"133","author":"JF Thibodeau","year":"2019","unstructured":"Thibodeau JF, Simard JC, Holterman CE, Blais A, Cloutier MP, Medeiros T, et al. PBI-4050 via GPR40 activation improves adenine-induced kidney injury in mice. Clin Sci (Lond). 2019;133:1587\u2013602.","journal-title":"Clin Sci (Lond)"},{"key":"1657_CR44","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3390\/ijms21030725","volume":"21","author":"A Gluba-Brz\u00f3zka","year":"2020","unstructured":"Gluba-Brz\u00f3zka A, Franczyk B, Olszewski R, Rysz J. The influence of inflammation on anemia in CKD patients. Int J Mol Sci. 2020;21:725.","journal-title":"Int J Mol Sci"},{"key":"1657_CR45","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000328037","volume":"32","author":"MI Yilmaz","year":"2011","unstructured":"Yilmaz MI, Solak Y, Covic A, Goldsmith D, Kanbay M. Renal anemia of inflammation: the name is self-explanatory. Blood Purif. 2011;32:220\u20135.","journal-title":"Blood Purif"},{"key":"1657_CR46","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1182\/blood.V79.8.1987.1987","volume":"79","author":"WC Faquin","year":"1992","unstructured":"Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992;79:1987\u201394.","journal-title":"Blood"},{"key":"1657_CR47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.stem.2023.12.003","volume":"31","author":"M Liu","year":"2024","unstructured":"Liu M, Zhang C, Gong X, Zhang T, Lian MM, Chew EGY, et al. Kidney organoid models reveal cilium-autophagy metabolic axis as a therapeutic target for PKD both in vitro and in vivo. Cell Stem Cell. 2024;31:52\u201370.e8.","journal-title":"Cell Stem Cell"},{"key":"1657_CR48","doi-asserted-by":"publisher","first-page":"F695","DOI":"10.1152\/ajprenal.00166.2023","volume":"325","author":"N Tabibzadeh","year":"2023","unstructured":"Tabibzadeh N, Satlin LM, Jain S, Morizane R. Navigating the kidney organoid: insights into assessment and enhancement of nephron function. Am J Physiol Ren Physiol. 2023;325:F695\u2013F706.","journal-title":"Am J Physiol Ren Physiol"},{"key":"1657_CR49","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.stem.2022.06.005","volume":"29","author":"T Tran","year":"2022","unstructured":"Tran T, Song CJ, Nguyen T, Cheng SY, McMahon JA, Yang R, et al. A scalable organoid model of human autosomal dominant polycystic kidney disease for disease mechanism and drug discovery. Cell Stem Cell. 2022;29:1083\u20131101.e7.","journal-title":"Cell Stem Cell"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01657-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01657-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01657-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T15:02:48Z","timestamp":1768575768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01657-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1657"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01657-w","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}